BMEA

4 - Biomea Fusion, Inc. (0001840439) (Issuer)

4 - Biomea Fusion, Inc. (0001840439) (Issuer)

COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapyTopline 26-week primary endpoint data from both Phase II studies anticipated 4Q 2026 SAN CARLOS, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the first patient has been dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, evaluating icovamenib in patients with type 2 diabetes ("T2D"), marking a key step in advancing icovame

10-K - Biomea Fusion, Inc. (0001840439) (Filer)

8-K - Biomea Fusion, Inc. (0001840439) (Filer)

Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026Completed 52-week follow-up from Phase II trial COVALENT-112 (icovamenib in type 1 diabetes) with data expected in the second quarter of 2026Initiated Phase I trial enrollment of GLP-131 (BMF-650 in obesity) with initial 28-day weight reduction data expected in the second quarter of 2026Projected cash runway into the first quarter of 2027 SAN CARLOS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, toda

SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea," "Biomea Fusion," or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral presentation at the 19th International Conference on Advanced Technologies & Treatments for Diabetes ("ATTD") in Barcelona on March 14, 2026 highlighting positive 52-week follow-up results from the Company's Phase II COVALENT-111 study evaluating the efficacy, safety, and tolerability of icovamenib in patients with type 2 diabetes ("T2D"). "We are encouraged by the durability of icovamenib's effect observed nine months post-dosing at Week 52," said

8-K - Biomea Fusion, Inc. (0001840439) (Filer)

SAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Company" or "Company management") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference: Biomea will present virtually on February 26, 2026, at 10:00 AM (EDT). Company management will also meet with investors in one-on-one meetings during the conference.The Citizens Life Sciences Conference: Biomea will present at 2:50 PM (EDT) on March 10, 2026, in Miami, FL. Company management will also meet with investors in one-on-one meetings during the confer

SCHEDULE 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

SCHEDULE 13G/A - Biomea Fusion, Inc. (0001840439) (Subject)

5 - Biomea Fusion, Inc. (0001840439) (Issuer)

8-K - Biomea Fusion, Inc. (0001840439) (Filer)

Rodman & Renshaw initiated coverage of Biomea Fusion with a rating of Buy and set a new price target of $8.00

Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes ("T2D") and in T2D patients currently failing glucagon-like peptide-1 ("GLP-1") based therapiesSuccessfully completed icovamenib food-effect study, establishing optimal dosing conditions to support late-stage clinical studies Successfully completed icovamenib chronic toxicology studies, supporting potential flexibility to evaluate clinical dosing beyond the validated 12-week regimenAdvancing BMF-650 through clinical development as an oral next-generation GLP-1 receptor agonist candidate designed to deliver effective and patient-friendly metabolic bene

S-8 - Biomea Fusion, Inc. (0001840439) (Filer)

SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 from 5:15 PM to 5:55 PM Pacific Time. Additionally, Biomea's management team will host one-on-one meetings throughout the conference, which will take place from January 12-15. A live audio webcast of the presentation can be accessed here or by visiting the Investors & Media section of Biomea's website at https://investors.biomeafusion.com/news-events/events

4 - Biomea Fusion, Inc. (0001840439) (Issuer)

Key Opinion Leader, Dr. Ralph DeFronzo presents the "Future of Menin Inhibitors" and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (NASDAQ:BMEA), a clinical stage diabetes and obesity company, today announced the release of a KOL interview during the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) featuring Dr. Ralph DeFronzo, Professor of Medicine and Chief of the Diabetes Division at UT Health San Antonio. The interview highlights the growing body of preclinical and clinical findings supporting the use of icovamenib in patient

SCHEDULE 13G - Biomea Fusion, Inc. (0001840439) (Subject)

SAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it presented COVALENT-111 study results at the 23rd WCIRDC which took place December 3-6, 2025 in Los Angeles, California. The data showed durable glycemic and c-peptide improvements with icovamenib, a menin inhibitor targeting beta-cell restoration in insulin deficient type 2 diabetes. "I am very pleased that our data was selected for an oral presentation at the WCIRDC meeting this year. Over the past 24 months, our clinical studies have shown that selective inhibition of menin can meani

4 - Biomea Fusion, Inc. (0001840439) (Issuer)

4 - Biomea Fusion, Inc. (0001840439) (Issuer)

SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity company, today announced that it has been selected for an oral presentation of its long-term icovamenib follow up data at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles, California on December 3-6, 2025. The Congress showcases cutting-edge developments from both emerging investigators and world-renowned leaders. "We are delighted to present our Week 52 long-term follow up data at WCIRDC, a meeting renowned for showcasing exciting advances in diabet

SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on November 26, 2025, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase 7,500 shares of the Company's common stock. The shares underlying each employee's stock options will vest 1/16 on a quarterly basis over four years, subject to such employee's continued employment with the Company on such vesting dates. The above-described award was made under Biomea's 2023 Inducement Equity Plan (the "Plan"). The above-described award wa